Wireless visual cortical stimulator devices are visual prostheses that help blind people regain their functional vision. It offers an electrical stimulator that activates viable cells rather than defective retinal cells in order to produce visual perception. On October 26, 2016, Second Sight reported the first implantation of Orion I Visual Cortex Prosthesis (Orion I), a wireless visual cortical stimulator, in a 30-year blind patient to offer human proof for the continued development of Orion I Visual Cortical Prosthesis (Orion I). Second Sight's Argus II System, a visual cortex stimulator that offers electrical stimulation that bypasses dead retinal cells to activate living cells, received FDA approval in 2013.With Orion I, alternative wireless technology is used instead of the wired technology used by Argus II.
The gadget can restore vision to individuals who are entirely blind as a result of glaucoma, cancer, diabetic retinopathy, or trauma. The initial implantation demonstrated that the gadget detects and localizes individual light spots while causing no adverse effects. Though the first human test of Orion I, wireless visual cortex stimulator showed to be able to treat visually impaired individuals with no adverse effects, technical advancement seldom gives string opportunities. The business plans to submit an application to the FDA in early 2017 for the initial completion of a clinical study of the entire system.
The market for wireless visual cortical stimulators is divided into two categories: indication type and end-users. The market is divided into cancer, diabetic retinopathy, trauma, glaucoma, and other indications based on the kind of indication. Diabetic retinopathy and glaucoma are projected to account for a significant portion of the entire market. Hospitals, ambulatory surgery centers, emergency care units, specialty clinics, and others are among the end-users in the visual cortical stimulator industry.